(Q43797985)

26 November 2017

title

Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy (English)

1 reference

26 November 2017

1 reference

Tsutomu Tanaka

1

1 reference

26 November 2017

Masafumi Ikeda

2

1 reference

26 November 2017

Takuji Okusaka

3

1 reference

26 November 2017

Hideki Ueno

4

1 reference

26 November 2017

Chigusa Morizane

5

1 reference

26 November 2017

Atsushi Hagihara

6

1 reference

26 November 2017

Satoru Iwasa

7

1 reference

26 November 2017

Yasushi Kojima

8

1 reference

26 November 2017

language of work or name

1 reference

8 October 2008

1 reference

Japanese Journal of Clinical Oncology

26 November 2017

published in

1 reference

26 November 2017

volume

38

1 reference

26 November 2017

issue

11

1 reference

26 November 2017

page(s)

755-761

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

26 November 2017

1 reference

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Phase I trial of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

The impact of anaemia on outcome in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

Cytokines in the pathogenesis of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYN098

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYN098

1 reference

26 November 2017

1 reference